Sponsors
Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. With a heritage of more than 120 years, the company has built a unique expertise and continues to advance the field of allergy care through innovation, research, and close collaboration with the medical community.
Operating in 45 countries, Stallergenes Greer offers a broad portfolio of formulations designed to provide healthcare professionals with innovative, safe and effective solutions tailored to the needs of people living with allergies. Its purpose is enabling precision medicine to improve life for people with allergies, a commitment which guides the company's strategy, product development and partnerships worldwide.
As part of its ongoing global expansion, Stallergenes Greer recently entered into an exclusive partnership with Nuance Pharma to expand its presence in China. This partnership reflects the company's determination to make allergen immunotherapy more widely accessible and to address the significant and growing burden of allergic diseases worldwide.
Who we are
We are a focused biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
We aim to positively impact the health of more than 2.5 billion individuals by the end of the decade with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.
What we do
We prevent and treat disease with specialty medicines, vaccines and general medicines.
We focus on the science of the immune system and advanced technologies, investing in 4 core therapeutic areas (respiratory, immunology and inflammation; oncology; HIV; and infectious diseases) to impact health at scale.
We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust.
Our portfolio
Specialty Medicines: Our specialty medicines prevent and treat diseases, from HIV, cancer and asthma to immune-inflammation diseases like lupus.
Vaccines: Our broad vaccines portfolio targets infectious diseases at every stage of life.
General Medicines: From antibiotics to inhaled medicines for asthma and COPD, we have a broad portfolio of general medicine products, many of them leaders in their class, making life better for millions of people worldwide.
For more information, please visit: www.gsk.com.
Orient EuroPharma Founded in 1982, Orient EuroPharma (OEP) was listed on the Taiwan Stock Exchange in 2003. With operations in pharmaceuticals, baby and adult nutrition, and dermo-cosmetics, OEP ranked as Taiwan’s 8th largest pharmaceutical company in 2023. The group has over 920 employees and 11 overseas subsidiaries, with manufacturing sites certified by the U.S. FDA and PIC/S GMP. Its flagship brand, Karihome, is a leading goat milk brand in the Asia-Pacific region, providing quality nutrition for all ages.
The Nestlé Nutrition Institute (NNI), as a non-for-profit association in Switzerland (in some parts of the world NNI operates under the brand Wyeth Nutrition Science Center - WNSC), shares leading science-based information and education with practicing health professionals in all parts of the world. NNI/WNSC is committed to fostering the highest levels of discussion within scientific community and build nutrition knowledge globally. All NNI/WNSC exclusive resources are available at http://www.nestlenutrition-institute.org and http://wyethnutritionsc.org.
PT Prodia Widyahusada Tbk (Prodia) is Indonesia’s leading clinical laboratory with over 360 outlets in 80 cities. Accredited by the College of American Pathologists (CAP), Prodia offers more than 3,000 tests, including genomics and precision medicine services. With 52 years of excellence, Prodia is committed to quality diagnostics, innovation, and advancing healthcare for better patient outcomes.
Burly LLP is a leading Kazakhstan-based pharmaceutical company established in 1997. We specialize in allergen extraction and the production of tablet allergens «Antipollin» for advanced allergy immunotherapy. Our products are trusted in CIS countries, Europe, and Asia. Combining innovation, quality, and reliability, «Burly» partners with healthcare providers worldwide to expand access to effective allergy diagnosis and treatment solutions, improving lives of patients globally.
Euroimmun (part of Revvity) is a leading provider of medical laboratory solutions for broad range of diagnostic specialties, including allergy, autoimmunity, infectious diseases, endocrinology, neurodegeneration and therapeutic drug monitoring.
The allergy portfolio encompasses a comprehensive menu of singleplex and multiplex assays for specific IgE detection, complemented by advanced instrumentation for flexible and efficient diagnostic testing.
PT. Indolabtek Dinamika was established in 1993 as a private company. Located in Jakarta - Indonesia, our main business are in trading and agency for medical diagnostic - clinical laboratory product. We provide the products and services for our customers ranging from small healthcare, clinical laboratory to hospital.
We believe that our products will be one of our customers solution to get better results in laboratory test. We bring them precision products that are not just reliable but also easy to use at very reasonable price.
In order to support our business across Indonesia, we have established extensive distribution network with our local partners-sub distributors all around Indonesia.
Takeda Creating better health for people and a brighter future for the world is our purpose. The science and technology we advance are constantly evolving. But through our enduring values, our ambition remains steadfast. We strive to deliver truly transformative treatments, contributing significant value to society while creating an exceptional experience for our people.
Supported By

Dear Friends and Colleagues,
The Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI), in partnership with the Indonesian Society of Allergy and Immunology (ISAI), will host the APAAACI 2025 Congress from 9 to 12 October 2025, in Jakarta, Indonesia. The theme of the congress is “Unity in Diversity: Advancing Science and Innovation in Allergy, Asthma, and Immunology - From Genetics to Cell-Based Therapies.”
The congress aims to blend cutting-edge scientific advancements with practical clinical insights, catering to both clinicians and researchers. With participation from international and regional experts, this event will foster knowledge sharing and meaningful collaborations in addressing allergic and immunologic diseases.
On behalf of APAAACI and ISAI, we warmly invite our industry partners to be part of this valuable Congress. Your support will be crucial in ensuring that the Congress is a scientifically enriching experience for all attendees. Together, we can make a positive impact on the community at large. Let’s work together to make the APAAACI 2025 Congress a resounding success
We look forward to your enthusiastic participation!
Prof. Amir HA Latif
Congress Chair
Prof. Ruby Pawankar
Congress Chair
Prof. Iris Rengganis
Congress Co-Chair
Sponsorship and Exhibition opportunities, please contact:
Mr. Obed Khan
Sponsorship & Exhibition Manager
+971 (50) 9973539
obed.khan@wearemci.com
ABOUT APAAACI
Our specialty is evolving. Allergic diseases and asthma are a rapidly growing health problem worldwide with a marked socio-economic impact. Alongside the rapid environmental (climate change, pollution, etc) and lifestyle changes, the fast-evolving economies of Asia-Pacific face the major brunt of the burden of allergic diseases.